July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Quality of Life and Dry Eye Disease Severity in People with Diabetes
Author Affiliations & Notes
  • Suzanne Hagan
    Life Sciences, Glasgow Caledonian University, Glasgow, SCOTLAND, United Kingdom
  • Mungunshur Byambajav
    Life Sciences, Glasgow Caledonian University, Glasgow, SCOTLAND, United Kingdom
  • Rema Elshein
    Life Sciences, Glasgow Caledonian University, Glasgow, SCOTLAND, United Kingdom
  • Andrew Collier
    Diabetes Day Centre, University Hospital Ayr, Ayr, United Kingdom
    Life Sciences, Glasgow Caledonian University, Glasgow, SCOTLAND, United Kingdom
  • Sven Jonuscheit
    Life Sciences, Glasgow Caledonian University, Glasgow, SCOTLAND, United Kingdom
  • Footnotes
    Commercial Relationships   Suzanne Hagan, None; Mungunshur Byambajav, None; Rema Elshein, None; Andrew Collier, None; Sven Jonuscheit, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 4865. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Suzanne Hagan, Mungunshur Byambajav, Rema Elshein, Andrew Collier, Sven Jonuscheit; Quality of Life and Dry Eye Disease Severity in People with Diabetes. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4865.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To assess the interrelationship between the severity of dry eye disease (DED) and the quality of life (QoL) in people with diabetes.

Methods : A pilot study of subjects with diabetes (n=17) and without diabetes (n=16, controls) investigated the severity of DED using the Ocular Surface Disease Index (OSDI) questionnaire, and QoL using the Dry Eye-related Quality of Life Score (DEQS) questionnaire. Subjects also underwent objective clinical assessment for DED, via the Schirmer I test (tear volume) and NITBUT (tear quality). Demographic and related medical information (i.e. presence of diabetic retinopathy [DR], HbA1c levels and duration of diabetes) was also assessed.

Results : DED symptoms were noted in 58.8% of subjects with diabetes (17.65% mild, 11.76% moderate and 29.41% severe), and in 25% of controls (mild DED only). Moreover, DED severity was significantly higher in those with diabetes (OSDI=22.9±22.0) versus controls (OSDI=7.4±5.6; p=0.034). Diabetic patients also showed a significantly lower QoL (DEQS=31.6 ±25.2) than controls (DEQS=9.1±8.2; p=0.002). No significant difference was noted for the tear volume (Schirmer) between those with diabetes (14.9±11.9) and controls (20±10.7; p=0.136). However, tear quality (NITBUT) was significantly reduced in diabetic subjects (8.5±2.9 secs) versus controls (10.6±3.4 secs; p=0.026).
A strong positive association was found between the severity of DED and its effect on QoL of diabetic participants (p<0.001; Spearman’s rho=0.912). DED was not associated with duration of diabetes, HbA1C level or DR. In those with diabetes, the study detected a moderate negative correlation between OSDI and NITBUT (p=0.011; Spearman’s rho=-0.617), but there was no correlation between tear volume (Schirmer) and DED severity (OSDI; p=0.806, Spearman’s rho=0.064).

Conclusions : This study demonstrated a strong positive association between severity of DED and reduced QoL in diabetic participants. This suggests that diabetes has a greater impact on DED-related QoL of this patient demographic. Therefore, clinical assessment and screening for DED should be included in routine follow-up of patients with diabetes

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×